Class status denied in Neurontin off-label suit
This article was originally published in Scrip
Executive Summary
Judge Patti Saris of the US District Court for the District of Massachusetts denied on May 15th a renewed request to "certify" as a class action a proposed national class of consumer and third-party payers in a suit against Pfizer over alleged fraudulent promotion of the epilepsy drug Neurontin (gabapentin) for off-label indications. Plaintiffs were seeking economic damages only.